The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | IMPACT: a UK clinical trials programme for hemonc patients post-transplant
The University of Birmingham has partnered with Leuka, NHS Blood and Transplant, and Anthony Nolan to deliver the UK’s first large-scale clinical trials programme for patients who receive stem cell transplants; IMPACT. In this interview, Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the aims of IMPACT, highlighting the huge unmet need it will fill, as well as the potential insights into the biological mechanisms of transplant it could provide. Prof. Craddock also provides an overview of the structure of IMPACT, including the first three studies that are taking place as part of the initiative. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
